The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate

Indian Journal of Human Genetics

Volumn 19, Issue 1, 2013, Pages 71-77

  Mogarekar, M R ^a   Chawhan, Seema S ^a  

^a SRTR Medical College   (India)

Author keywords

arylesterase; p nitrophenylacetate; paraoxon; Paraoxonase 1 polymorphism

Indexed keywords

4 NITROPHENYLACETIC ACID; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; PHENYLACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE FREQUENCY; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; OUTPATIENT; PHENOTYPE; POPULATION DISTRIBUTION; POPULATION GENETICS;

EID: 84879639332     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.112897     Document Type: Article

References (42)

1. Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a Multigene family. Genomics 1996; 33:498-507. (Pubitemid 26159866)
2. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119-120:379-88. (Pubitemid 29278574)
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69-76. (Pubitemid 26167018)
4. Hegele RA. Paraoxonase genes and disease. Ann Med 1999;31:217-224. (Pubitemid 29304460)
5. Durrington PN, B. Mackness, Mackness MI. Paraoxonase and Atherosclerosis. Arterioscler Thromb Vasc Bio. 2001; 21; 473-480.
6. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6. (Pubitemid 23063292)
7. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-90. (Pubitemid 28198486)
9. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-5. (Pubitemid 29072747)
10. Kim NS, Kang K, Cha MH, Kang BJ, Moon J, Kang BK, et al. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 2007; 364 (1):157-62. (Pubitemid 47599458)
11. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and it relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
12. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with noninsulin-dependent diabetes mellitus. Metabolism 1998; 47:598-602. (Pubitemid 28213122)
13. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al. Decrease of serum paraoxonase Activity in chronic renal Failure. J Am Soc Nephrol 1998; 9: 2082-8. (Pubitemid 28482156)
14. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci 2002;977:239-44. (Pubitemid 35418159)
15. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. J Hum Genet 2004; 49:474-81. (Pubitemid 39314366)
16. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003; 50:cclxxiii-cclxxv.
17. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003; 50:ccxxv-ccxxvii.
18. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344:796-8. (Pubitemid 24283963)
19. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;53:598-608. (Pubitemid 23311330)
20. Eckerson HW, Wyte CM, La Du BN. (1983) The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1983;35:1126-38. (Pubitemid 14201166)
21. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60. (Pubitemid 28098579)
22. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510-7. (Pubitemid 30366256)
23. Augustinsson, K.-B, Ekedahl, G. On the specificity of arylesterases. Acta Chem. Scand. 1962;16: 240-1.
24. Huggins C, Lapides J. Chromogenic substrates.IV. Acyl esters of p-nitrophenol as substrates for the colorimetric determination of esterase. J Biol Chem 1947; 770:467-482.
25. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43:230-8.
26. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
27. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 2008;1:147-152.
28. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
29. Hazardous Substance Fact Sheet. New Jersy: Department of Health and Senior Services: Nj.gov/health/eoh/rtkweb/documents/fs/1457.pdf p. 1-6.
30. Furlong CE, Cole TB, Jarvik GP, Costa LG. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 2002;3:341-8. (Pubitemid 34567571)
31. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-6.
32. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371-92. (Pubitemid 37386402)
33. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000;20:2441-7.
34. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999;9:745-53. (Pubitemid 30011938)
35. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7. (Pubitemid 34219807)
36. Brophy VH, Jarvik GP, Furlong CE. PON1 polymorphism. In: Costa LG, Furlong CE, editor. Paraoxonase (PON1) in health and disease: Basic and Clinical Aspects. Norvell, MA: Kluwer Acad; 2002.p. 53-77.
37. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch Pharmacol 2004;369:78-88. (Pubitemid 38161225)
38. Mackness M, Durrington P, Mackness MI. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004;15:399-404. (Pubitemid 39061619)
39. Ruiz J, Blanchex H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-872.
40. Flekac M, Skrha J, Zídková K, Lacinová Z, Hilgertová J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008;57:717-26
41. Lee CH, Lee KY, Choe KH, Hong YC, Kim YD, Kang JW, et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Pub Health 2005; 38:345-50.
42. Kucukali CI, Aydin M, Ozkok E, Orhan N, Cakir U, Kilic G, et al. Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population. Psychiatr Genet 2008;18:289-94.